ArticleEuropean journal of nuclear medicine and molecular imaging2026
Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Transformer-Based PET/CT Fusion Enables Preoperative Prediction and Prognostic Stratification of Spread Through Air Spaces in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated tumor habitat and metabolic hot spot displacement analysis on [¹⁸F]FDG PET/CT for predicting treatment response and progression in unresectable locally advanced NSCLC: a two-center competing risk study.European journal of nuclear medicine and molecular imaging · 2026Article
- Reproducibility and Potential Prognostic Value of Spatial Metabolic PET Metrics in Oral Tongue Squamous Cell Carcinoma.Cancers · 2026Article
- Development and validation of a machine learning model for identifying liver fibrosis in MAFLD: a retrospective model development study.BMC medical informatics and decision making · 2026Article
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
- Metastatic patterns, prognostic factors, and deep learning model development in primary gastrointestinal melanoma: a retrospective cohort analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate non-invasive prediction of histopathologic invasiveness and recurrence risk remains a clinical challenge in resectable non-small cell lung cancer (NSCLC). We developed and validated the Edge Proximity Score (EPS), a novel [
methodsThis retrospective study included 244 NSCLC patients with preoperative [
resultsEPS was significantly elevated in tumors with LVI, VPI, and STAS (P < 0.001), consistently ranked among the top SHAP features, and was an independent predictor of PFS (HR = 2.667, P = 0.015). The EPS-based nomogram achieved AUCs of 0.67, 0.70, and 0.68 for predicting 1-, 3-, and 5-year PFS in the TCIA validation cohort. High EPS was associated with proliferative and metabolic gene signatures, whereas low EPS was linked to immune activation and neutrophil infiltration.
conclusionEPS is a biologically relevant, non-invasive imaging biomarker that may improve risk stratification in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.